{"id":"NCT04152083","sponsor":"H. Lundbeck A/S","briefTitle":"A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine","officialTitle":"A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-07","primaryCompletion":"2020-07-08","completion":"2020-07-08","firstPosted":"2019-11-05","resultsPosted":"2021-08-16","lastUpdate":"2021-08-17"},"enrollment":485,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Eptinezumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Eptinezumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of eptinezumab administered intravenously in participants experiencing an acute attack of migraine.","primaryOutcome":{"measure":"Time to Headache Pain Freedom","timeFrame":"Up to 48 hours postdose","effectByArm":[{"arm":"Eptinezumab","deltaMin":4,"sd":null},{"arm":"Placebo","deltaMin":9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0006"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":10},"locations":{"siteCount":57,"countries":["United States","Georgia"]},"refs":{"pmids":["35902796","35659622","35130832","34128999"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":238},"commonTop":["Hypersensitivity"]}}